The Evaluation of CD3, CD 5, CD10, CD 19, and CD20 Markers in the Differential Diagnosis of the Lymphoma Subtypes in Sudanese Patients

Mohamed Elfatih Abdelwadoud, Nabawia S. Ahmed, Hadia Alhaj, Hisham Ali Waggiallah

International Journal of Biomedicine. 2021;11(4):493-497.
DOI: 10.21103/Article11(4)_OA14
Originally published December 10, 2021


The objective of this paper was to evaluate the use of CD3, CD5, CD10, CD19, and CD20 markers in the differential identification of lymphoma subtypes.
Methods and Results: This was a retrospective cross-sectional study included 82 patients with palpable lymphadenopathies. The formalin-fixed paraffin block sections  immunostained with the Dako flex were investigated. CD3, CD5, CD10, CD19, and CD20 staining was performed on sections. The current study found that the two main types of lymphoma, Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, have a significant association with CD3, CD10, and CD19, and a highly significant association with CD20, implying that these CD markers are crucial for general classification and diagnosis of lymphoma. CD3 had a highly significant relationship with gender. CD3 and CD20 were demonstrated to have a significant relationship with the lymphoma subtypes. The CD20 marker is the most consistent and useful marker for differentiating lymphoma subtypes.

Hodgkin’s lymphoma • non-Hodgkin’s lymphoma immunohistochemistry • CD markers
  1. Patel HS, Shah S, Goswami HM.  Role of Immunohistochemistry in Differential Diagnosis of Lymphoma (A Study of 200 Cases). International Journal of Contemporary Pathology, 2020; 6(1):23-28
  2. Dong HY, Gorczyca W, Liu Z, Tsang P, Wu CD, Cohen P, Weisberger J. B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol. 2003 Feb;119(2):218-30. doi: 10.1309/u98advkuc26r2rja. 
  3. Campbell SM, Peters SB, Zirwas MJ, Wong HK. Immunophenotypic diagnosis of primary cutaneous lymphomas: a review for the practicing dermatologist. J Clin Aesthet Dermatol. 2010 Oct;3(10):21-5. 
  4. Hsu SM, Tseng CK, Hsu PL. Expression of p55 (Tac) interleukin-2 receptor (IL-2R), but not p75 IL-2R, in cultured H-RS cells and H-RS cells in tissues. Am J Pathol. 1990 Apr;136(4):735-44.
  5. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991 Oct;139(4):701-7. 
  6. Pinkus GS, Said JW. Hodgkin's disease, lymphocyte predominance type, nodular--further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker. Am J Pathol. 1988 Nov;133(2):211-7. 
  7. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Müller-Lantzsch N, Stein H. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4766-70. doi: 10.1073/pnas.88.11.4766. 
  8. Gonzalez CL, Medeiros LJ, Jaffe ES. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma. Am J Clin Pathol. 1991 Jul;96(1):81-9. doi: 10.1093/ajcp/96.1.81. 
  9. Pan Z, Chen M, Zhang Q, Wang E, Yin L, Xu Y, Huang Q, Yuan Y, Zhang X, Zheng G, Yuan J. CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. Mod Pathol. 2018 May;31(5):718-731. doi: 10.1038/modpathol.2017.177. 
  10. Wu B, Vallangeon B, Galeotti J, Sebastian S, Rehder C, Wang E. Epstein-Barr virus-negative diffuse large B cell lymphoma with aberrant expression of CD3 and other T cell-associated antigens: report of three cases with a review of the literature. Ann Hematol. 2016 Oct;95(10):1671-83. doi: 10.1007/s00277-016-2749-0. 
  11. Lee M, Cha HJ, Yoon DH, Suh C, Huh J. EBV-positive diffuse large B-cell lymphoma of the elderly with aberrant expression of CD3 and TIA-1. Blood Res. 2013 Jun;48(2):156-60. doi: 10.5045/br.2013.48.2.156.
  12. Sun J, Medeiros LJ, Lin P, Lu G, Bueso-Ramos CE, You MJ. Plasmablastic lymphoma involving the penis: a previously unreported location of a case with aberrant CD3 expression. Pathology. 2011 Jan;43(1):54-7. doi: 10.1097/PAT.0b013e328340bbba. 
  13. Na HY, Choe JY, Shin SA, Kim HJ, Han JH, Kim HK, Oh SH, Kim JE. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors. PLoS One. 2019 Oct 23;14(10):e0224247. doi: 10.1371/journal.pone.0224247. 
  14. Campbell SM, Peters SB, Zirwas MJ, Wong HK. Immunophenotypic diagnosis of primary cutaneous lymphomas: a review for the practicing dermatologist. J Clin Aesthet Dermatol. 2010 Oct;3(10):21-5. 
  15. Khandakar B, Wang W, Li S. Primary splenic red pulp diffuse large B-cell lymphoma with anaplastic features. Stem Cell Investig. 2016 Apr 6;3:9. doi: 10.21037/sci.2016.03.04. 
  16. Katchi T, Liu D. Diagnosis and treatment of CD20 negative B cell lymphomas. Biomark Res. 2017 Feb 7;5:5. doi: 10.1186/s40364-017-0088-5.

Download Article
Received August 16, 2021.
Accepted August 27, 2021.
©2021 International Medical Research and Development Corporation.